|
|
News Breaks | | | | February 11, 2013 | | 09:57 EDT |  | REGN, SNY | Regeneron says Sanofi intends to acquire Regeneron common stock
Regeneron (REGN) announced that it received from Sanofi (SNY) a notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 that Sanofi intends to acquire Common Stock of Regeneron through open market purchases and direct purchases from shareholders. As a result, Sanofi intends that the value of its ownership of voting securities of Regeneron stock will be in excess of the $500M HSR Act notification threshold. | |
|
News For REGN;SNY From The Last 14 Days Check below for free stories on REGN;SNY the last two weeks. |
|
|
| June 18, 2013 | | 11:52 EDT |  | REGN | Stocks with call strike movement; REGN MU
 Subscribe for More Information | | | 08:38 EDT |  | SNY | Sanofi management to meet with JPMorgan
Subscribe for More Information | | | 08:36 EDT |  | REGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. | | | June 13, 2013 | | 11:02 EDT | | SNY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | June 10, 2013 | | 07:20 EDT | | SNY | Biomed to host a conference
Subscribe for More Information | | | 07:03 EDT | | SNY | Sanofi announces FDA approved sBLA for licensure of influenza vaccine
Subscribe for More Information | | | June 6, 2013 | | 05:49 EDT | | REGN | Regeneron, Bayer reports positive Phase 3 results for Eylea
Regeneron Pharmaceuticals (REGN) and Bayer HealthCare (BAYRY) announced positive top-line results for EYLEA Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization. In this trial, patients receiving EYLEA at an initial dose of 2 milligrams, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared to a loss of 2.0 letters in patients receiving sham injections. The most common adverse events observed in the MYRROR trial that occurred with a frequency of 2% or more were conjunctival hemorrhage, dry eye, eye pain, headache and nasopharyngitis. | |
|
|
|
|
|
|
